• SPRWF subsidiary Blissco recently received Health Canada licensing approval to sell cannabis oils
• Blissco expected to produce more than seven million tincture bottles annually
• Supreme Cannabis says that the subsidiary will make a significant impact on its FY2020 revenues

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of cannabis companies including subsidiary Blissco Cannabis Corp., announced that Blissco has received licensing approval from Health Canada for the sale of cannabis oils from its Langley, British Columbia, facility (http://ibn.fm/KvUBF). The highly anticipated licensing means that Blissco now has government approval to sell full spectrum cannabidiol (CBD) oil products.

Supreme Cannabis closed its acquisition of Blissco—a wellness cannabis brand and multiprocessor and distributor based in British Columbia—in the first quarter of FY2020 (http://ibn.fm/OYwtS). It has been making strategic moves toward this licensing milestone. By improving the efficiency and focus of Blissco’s business operations, including initiating construction on a large-scale ethanol-based extraction lab, Supreme Cannabis has been working to expand Blissco’s extraction capabilities. The company predicts that its facility will be able to produce over seven million tincture bottles annually, making the Blissco brand a significant driver to SPRWF’s projected revenue in FY2020.

The subsidiary’s ability to produce and sell high-quality CBD oil products means Blissco sales will be a significant factor in SPRWF’s projected FY2020 revenue. The company expects to launch its first CBD oil product in the Canadian market by the second quarter of FY2020 with plans to follow up that initial product offering with a suite of complementary cannabis extract products in subsequent quarters.

“With the receipt of the license and expanded extraction capacity, Blissco will be positioned to address the growing unmet demand for high-quality, CBD oil products across Canada,” said Supreme Cannabis CEO Navdeep Dhaliwal. “Blissco’s legacy of premium, whole-flower products established a brand that represents quality and authenticity to wellness consumers. For over a year, Blissco’s team developed advanced oil-processing and formulation capabilities based on the same ethos. Consumers will soon be able to experience high-quality CBD oil products from a premium wellness brand they have come to trust.”

In addition, SPRWF has appointed Todd McAdam as general manager of the Blissco facility; his responsibilities will include managing and supporting the production, sale, and distribution of Blissco’s high-quality products. A highly experienced operations professional, McAdam has spent more than 30 years working in the food and beverage industries. Most recently, he served as general manager at Labatt Breweries of Canada’s Turning Point Brewery in British Columbia.

In addition to Blissco, the Supreme Cannabis portfolio includes 7ACRES, an award-winning brand; Cambium Plant Sciences, a cultivation IP and plant-genetics company; Medigrow Lesotho, a Southern Africa cannabis-oil producer; Supreme Heights, the investment platform focused on CBD; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• The new strategic advisor, Dr. William Li, is a globally recognized medical professional
• One of Li’s primary specialties is the identification of unmet medical market needs that can be addressed through technological advances
• Endonovo is working to develop solutions for major therapeutic needs, especially in regard to pain management
• Its Electroceutical® SofPulse® is clinically proven to provide post-operative pain relief and speed up recovery

On September 30, 2019, Endonovo Therapeutics Inc. (OTCQB: ENDV), a commercial-stage developer of innovative medical devices, announced the appointment of Dr. William Li as a strategic advisor to the CEO. The role of Li would be to strategically explore growth opportunities within the Endonovo target markets, the company said in a press release (http://ibn.fm/mCqAT).

“Dr. Li is a globally recognized medical professional and a business visionary with a strong track record of success,” Endonovo Therapeutics CEO Alan Collier said in a news release. Just like the Endonovo team, Li sees the long-term potential of medical innovations and their ability to change the industry, Collier added.

According to Li, “Endonovo has a strong technology platform with game changing potential. The company’s clinical-stage wearable Electroceutical® therapeutic device, SofPulse®, can address pain, wound healing, post-surgical pain, edema, central nervous system disorders and various other conditions.”

“Endonovo is poised to go to the next level across a range of industry verticals. I look forward to working with Alan and the Endonovo team to evaluate the Company’s operational and strategic opportunities,” Li added.

One of Li’s focal areas of experience is the identification of unmet needs in the healthcare space, especially if cost-effective innovative technology can offer a solution.

Li is the CEO and co-founder of the Angiogenesis Foundation. He gained experience under the guidance of Dr. Judah Folkman – one of the angiogenesis pioneers. Li has been actively involved in angiogenesis and clinical research for more than 30 years. Li graduated from Harvard and completed his medical residency training at Massachusetts General Hospital in Boston. He serves as a consultant to various leading global public and private companies.

Endonovo Therapeutics is currently developing solutions to meet major therapeutic needs. The company’s innovative SofPulse® device delivers clinically proven post-operative pain relief for patients, reducing the need for opioid use.

SofPulse® delivers targeted pulsed electromagnetic field therapy to significantly speed up the recovery process after surgery. It improves the patient’s natural recovery experience and can be a better alternative to opioid-based pain medications, thus helping tackle the current opioid crisis.

According to U.S. federal statistics, opioids kill more people per year than automobile accidents. In 2018 alone, 68,000 Americans died of a drug overdose stemming from opioid abuse (http://ibn.fm/BsSiX). This is a significant increase from 18,515 opioid-related deaths in 2007.

The general population and the medical community are both pushing for a change in which chronic and post-operative pain are handled. Unfortunately, few alternatives to opioids exist. SofPulse® is one of the innovative solutions that could diminish the use of medications and give patients satisfactory pain management.

Endonovo’s therapy is cleared by the U.S. Food and Drug Administration for the palliative treatment of post-surgical pain and edema. It is also CE-marked in the European Economic Area for the promotion of wound healing and the palliative treatment of post-surgical pain and edema.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• In a YouTube interview, Supreme Cannabis CEO Navdeep Dhaliwal stated that investors should focus on the company’s strong balance sheet
• Supreme Cannabis reported $41.8 million in sales for FY2019, as compared to $8.9 million in FY2018, marking a 370 percent year-over-year jump; the company also reported its first positive adjusted EBITDA
• Dhaliwal further noted that the performance of subsidiary 7ACRES is key to the company’s growth

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1), a global diversified portfolio of cannabis companies, projects that its fiscal 2020 net revenues will increase to an estimated $150 million to $180 million, with a positive adjusted EBITDA. In FY2019, Supreme Cannabis reported net revenues of $41.8 million, including its first positive adjusted EBITDA quarter of $3.2 million (http://ibn.fm/PkcSB). FY2019 net revenue total itself was a 370 percent improvement compared to the company’s $8.9 million in cannabis sales posted for FY2018.

Supreme Cannabis CEO and director Navdeep Dhaliwal said during a YouTube interview with Evan Veryard, president of Capital 10X, that he believes the cannabis industry is entering a period where companies with strong business fundamentals will dominate.

“It’s an inflection point,” Dhaliwal noted in the interview in reference to Supreme Cannabis’ projections for FY2020 net revenues (http://ibn.fm/QiIVS). “You’re starting to see a real separation between strong businesses and strong core operations that are going to be strong, dominant long-term with competitive advantage. We’re excited about this period in the market because business fundamentals are going to take over and a lot of the noise is going to go away.”

In the interview, Dhaliwal noted that investors should look at the strong balance sheet of Supreme Cannabis. “We have a very healthy cash balance, and we’re fully funded for all our planned business objectives,” he observed, adding that Supreme Cannabis is in a good position to receive non-diluted debt financing from tier-one lenders and to “fulfill all of our obligations, specifically to debentures which are due in 2020 and 2021… It is really about balance: building strong businesses, investing prudently in growth and taking a data-driven approach. Test and validate and then a scale approach. That’s our strategy.”

As a diversified consumer-driven business, Supreme Cannabis is also focused on high-margin, premium quality products, Dhaliwal observed. The company wants to please its highly discerning consumers with the highest quality products. One example of that focus, he pointed out, is the company’s 7ACRES subsidiary, which recently launched Jack Haze, its first proprietary strain.

Jack Haze is 7ACRES’ first sativa-dominant strain with rare sensory characteristics (http://ibn.fm/ejmYM). Plans call for more unique strains to be introduced in the future as the company differentiates 7ACRES’ high-end flower offering and earns premium pricing across Canada.

The Supreme Cannabis portfolio includes 7ACRES, an award-winning brand; Cambium Plant Sciences, a cultivation IP and plant-genetics company; Medigrow Lesotho, a Southern Africa cannabis-oil producer; Supreme Heights, the investment platform focused on CBD; Blissco Cannabis Corp, a wellness cannabis brand and a multiprocessor and distributor based in British Columbia; and a brand partnership and licensing deal with Khalifa Kush Enterprises Canada.

For more information, visit the company’s website at www.Supreme.ca

NOTE TO INVESTORS: The latest news and updates relating to SPRWF are available in the company’s newsroom at http://ibn.fm/SPRWF

• IONIC Brands is a manufacturer of premium cannabis products with a diverse portfolio
• The company recently acquired Zoots Premium Cannabis and its variety of drops, gummies, energy shots, and hard candies, sold in Illinois, Washington, Colorado, and Massachusetts
• IONIC is also preparing to build on its patents for brewing cannabis-infused coffee, tea, and cocoa
• The edibles market was valued at approximately $2.4 billion in 2018 with expected revenues of about $11.6 billion by 2025

Recreational adult-use cannabis continues to make headlines amid growing legalization throughout North America, providing opportunities for national cannabis holdings company IONIC Brands Corp. (CSE: IONC) (OTC: IONKF) (FRA: IB3) and its portfolio of premium luxury products.

In the United States, Pennsylvania is contemplating legislation that could make it the eleventh state in the nation to legalize recreational-use marijuana in the birthplace of America’s revolution (http://ibn.fm/adRxP). Canada’s long-anticipated legalization of food-and-beverage cannabis products occurred October 17, opening the door for the first legal edibles and infused drinks to reach the market in December (http://ibn.fm/oaLTR). In Mexico, the Senate is expected to pass a bill during the coming week that could decriminalize marijuana if it is subsequently approved by the lower House and dodges an opposition referendum (http://ibn.fm/NtXgC).

Pro-cannabis fervor has swept much of the world during recent years following decades of prohibition that enhanced a black market eager to supply unabashed marijuana users. The sea change in societal opinion on the leafy plant’s products has fortified commercial enterprises operating above board in compliance with governmental regulations, including IONIC.

IONIC added Natural Extractions Inc., doing business as Zoots Premium Cannabis Infused Edibles, to its family of recreational cannabis products in July, welcoming an array of drops, gummies, energy shots and hard candies manufactured to offer consistent and reliable dosing that are sold at licensed marijuana retailers in Illinois, Washington, Colorado and Massachusetts (http://ibn.fm/yVls5).

The West Coast-based companies acknowledged a February Zion Market Research report that valued the global cannabis edibles market at approximately $2.4 billion in 2018 with expected revenues of about $11.6 billion by 2025 at a CAGR of around 25.4 percent between 2019 and 2025 (http://ibn.fm/1Xhx3).

IONIC also entered the infused beverage market with secured patents in the single-serve coffee and beverage pod market during the spring. The announced patents are among the first cannabis patents in the country’s history, slated for brewing cannabis-infused coffee, tea and cocoa from CannaCafe (http://ibn.fm/kyF7z) – a potential multi-billion-dollar market in its own right.

The company’s edibles and beverage offering provide alternatives to consumers put off by recent health concerns surrounding vape pen use for recreational cannabis use. The mysterious vaping-related disease that’s killed at least 26 people from 21 states since April has been branded EVALI, short for e-cigarette or vaping product use-associated lung injury, by the US Centers for Disease Control and Prevention (CDC), the federal health agency that acknowledged it has not been able to determine the precise cause(s) of EVALI and issued a recommendation against using any type of e-cigarette or vaping product until a proper conclusion can be reached (http://ibn.fm/H4fVH).

Because IONIC’s cornerstone products are vapes and related materials, the company issued a statement recently acknowledging a preponderance of evidence that appears to indicate the EVALI illnesses have resulted from illegal, black market vape use (http://ibn.fm/ybOCD). IONIC’s statement notes the company’s commitment to using only the highest quality materials, exclusively sourced from licensed producers of integrity that use state of the art equipment and ensure strict operating practices.

The company also notes it has never and will never use any additives that contain Vitamin E acetate or additives that are based on petrochemicals, two substances suspected of contributing to the EVALI outbreak.

For more information, visit the company’s website at www.IONIC.social

NOTE TO INVESTORS: The latest news and updates relating to IONKF are available in the company’s newsroom at http://ibn.fm/IONKF

• ETST’s super-critical extraction process from industrial hemp plants keeps plants’ natural occurring properties intact
• ETST plans expansion of CBD products over the next five years
• Company’s products offer “full spectrum” cannabinoid profile, whereas most cannabis companies focus on the benefits of CBD alone

Earth Science Tech Inc. (OTCQB: ETST), a diverse biotech company focused on the nutraceutical and pharmaceutical fields, offers a unique product line of full-spectrum cannabinoid oils that have a distinct advantage in the competitive nutraceutical market. ETST’s high-pressure, low-heat CO2 extraction process delivers seven distinct cannabinoids, maximizing all the natural therapeutic benefits of the industrial hemp plant (http://ibn.fm/DJdu2) (http://ibn.fm/rmGbz).

The unique process of extraction from industrial hemp plants grown by generational farmers in Oregon, Colorado, and Kentucky results in a full-spectrum cannabinoid oil that is natural and free from synthetic cannabinoids found in some competitors’ products. In addition, the CO2 extraction process results in more of the natural-occurring properties of the plant being left intact. ETST believes Its formulations and proprietary products are unique and distinguish the company from the competition. In its September 2019 SEC filing, Earth Science Tech said it plans to expand manufacturing and marketing of its CBD products over the next five years.

The ETST SEC filing and analysis report said the company intends to create CBD-rich hemp oil and other CBD-containing products unique to the current market in the nutraceuticals industry. Earth Science Tech believes its proprietary formulations set it apart from competing products for promoting health. The company intends to offer its line of health and nutrition products to consumers online and through brick-and-mortar clinics, pharmacies, and retail stores. ETST’s unique products include high-quality supplement brands and proprietary, CBD-rich hemp oil.

“We believe our high-grade, CBD-rich hemp oil contains the high-quality, natural CBD because it’s formulated using a wide array of cutting-edge technologies, including super-critical extraction process (CO2), isolation and micron filtration,” the SEC filing noted. “Super-critical extraction is a gentle approach and the key method in the extraction of our CBD. The method exploits the fact that CO2 at low temperature and under high pressure becomes liquid and thereby draws the cannabinoids and terpenes from the plant material.” The process results in more detectable amounts of important cannabinoids than found in some competitor products, ETST said. The company also noted that its hemp oil is lab tested multiple times throughout the manufacturing process, from seed to shelf. Tests include cannabinoid panel content, terpenoids, micros and residual solvents.

While many cannabis companies are touting the benefits of CBD only in their products, ETST’s products boast a cannabinoid profile with higher content and detectable amounts of other important cannabinoids. For consumers desirous of the full range of benefits cannabinoids have to offer, ETST’s “full spectrum” products deliver on that promise.

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

• Endonovo Therapeutics is developing a bioceutical device that provides an alternative to the prescription pain pills blamed for hundreds of thousands of deaths in recent years as part of a multinational opioid crisis
• Endonovo’s proprietary SofPulse® flagship device provides an electrical micro-current to the afflicted part of the body, particularly post-surgery, to minimize a patient’s need for pain relief medication
• A foot and ankle specialist in Ohio recently used the device following her own tendon surgery and provided a personal testimonial with a professional perspective of the device’s effectiveness in minimizing her pain
• The SofPulse® device is being evaluated professionally under a plan to be in up to 600 U.S. hospitals by the end of next year

When a foot and ankle medical specialist underwent surgery recently for her own tendon reconstruction need, she presented bioelectronic device maker Endonovo Therapeutics Inc. (OTCQB: ENDV) with a first-person professional perspective of Endonovo’s non-opioid pain relief solution that showcases Endonovo’s revolutionary potential for alleviating an international drug-dependency crisis.

In a home-made video, Dr. Jane Graenber, DPM, of the Foot and Ankle Wellness Center in Delaware, Ohio, attests that Endonovo’s SofPulse® electroceutical device has helped her to remain generally pain-free a day after the tendon surgery, such that she says she has only used three doses of Tylenol for relief (no prescription pain pills) during the interim since her procedure (http://ibn.fm/H2n5X).

“This device is putting out a micro-current to my surgical area every two hours… And it’s taken care of the pain, and I’m sitting here very comfortably,” Graenber states in the video. “At our practice we may be starting to include this post-operatively as an option to reduce pain. This was a pretty big surgery and I’m really very comfortable. So I’m giving credit to a good surgeon but also a new device that may revolutionize pain (treatment) after surgery.”

Endonovo announced its initial strategy to begin a national rollout of the SofPulse® on June 13 with plans to be in the evaluation stage at 600 U.S. hospitals through the end of next year (http://ibn.fm/P0w4a). Graenber identifies the video’s date as August 3, countering a time stamp at the bottom of the video that says it was recorded in January 2015.

The proliferation of opioids for pain relief following medical procedures during the past two decades has generated worldwide concerns about the prescription pills’ apparent role in creating patients’ ensuing drug addictions – addictions that have been cited in the deaths of hundreds of thousands of people. The Centers for Disease Control and Prevention states that as of 2017, its statistics showed an average of 130 Americans were dying every day from an opioid overdose (http://ibn.fm/4e49T).

The concerns about opioid abuse have sparked a multi-national sea change in attitudes regarding marijuana use as a medical therapy, although the cannabis plant’s products remain controversial with many governmental regulators. Endonovo’s SofPulse® provides a non-drug alternative to treating pain relief, entirely bypassing concerns about potential substance abuse and harmful side effects.

Furthermore, a recent scientific study of patient outcomes is countering the popularly held idea that marijuana reform is reducing the number of opioid-related deaths. The study published in the Proceedings of the National Academy of Sciences of the United States of America (PNAS) in June found that states where cannabis legislation has eased access to medical marijuana as an alternative to opioids have actually seen an increase in opioid-related deaths in recent years, rather than a decrease (http://ibn.fm/0BsyR).

“Cannabinoids have demonstrated therapeutic benefits, but reducing population-level opioid overdose mortality does not appear to be among them,” the study states.

Endonovo’s therapy platform has received clearance for the palliative treatment of post-operative pain and swelling from the U.S. Federal Drug Administration, insurance coverage for chronic wound treatment from the national Centers for Medicare and Medicaid Services, and a CE-mark certification that denotes conformity with European Economic Area health and environmental standards related to wound, pain and edema treatment.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://ibn.fm/ENDV

• Neutra Corp. subsidiary VIVIS recently announced the formal release of its hemp-based transdermal skin cream
• Neutra Corp. is an early-stage research and development company that is interested in developing products for healthy living, particularly relating to air quality and the use of CBD products derived from hemp
• The company is interested in the development and retail of hemp-based cannabidiol products such as skin creams, which can be used by athletes and sports enthusiasts
• Neutra Corp. acquired VIVIS in September 2019 to increase the company’s presence in the growing CBD market sector

Neutra Corp. (OTCQB: NTRR) is an early stage research and development company that was founded in 2015. Neutra Corp. is interested in new technologies, particularly in the nutraceuticals area. It aims to find healthy solutions for living in today’s world. To this end, the company aims to develop and bring to market products that are natural and organically based.

Neutra Corp. is interested in developing into a vertically integrated company, able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products effectively, with the announced market release of a new transdermal (http://ibn.fm/YKbUS), hemp-based sports cream the company believes will be a hit with both amateur and pro athletes, and others seeking relief after tough workouts and performances. In fact, the market for hemp-based cannabidiol products has proven to be lucrative with sales in 2018 alone of up to $390 million. Projected sales in the next couple of years is expected to be a few billion dollars.

The forecast is that consumer interest and sales in CBD and CBD-derived products is going to substantially increase in the future and, thus, a company in this industry is likely to profit greatly in the coming years, which is what Neutra Corp. recognizes. The interest in cannabidiol and CBD-based products has shown tremendous growth over the last couple of years, and more growth is likely to occur as legislation changes to allow more items to be developed and sold to consumers.

Neutra Corp. is interested in forging business relationships so as to help with the goal to develop creams and supplements within the hemp-derived CBD marketplace. Therefore, Neutra Corp. recently acquired VIVIS in September 2019 – in order to increase the presence of Neutra Corp. in the CBD market sector. VIVIS is a retail brand of products that are derived from hemp. In addition, these products from VIVIS are all certified to be of high purity and contaminant-free. All of these products are third-party tested, which falls in line with Neutra Corp.’s aim to develop natural and organic products that are safe for the environment. The idea is that Neutra Corp. will be able to expand further into the market for hemp-derived products through this recent acquisition of VIVIS (http://ibn.fm/syVuV).

Neutra Corp. subsidiary VIVIS has now announced the formal release of their hemp-based transdermal skin cream. There is a large market of athletes who are potentially interested in skin creams and other products derived from hemp-based CBD. Skin creams can be very helpful for treating discomfort that athletes may experience because of their physical activity.

Neutra Corp. is particularly interested in products that have been designed for athletes and active Americans, and it is likely that the sports medicine and nutrition market will grow in the future. Sports nutrition sales are also projected to reach $11 billion by 2023. As more people become involved with sports and athletics, the market for creams and supplements can be expected to grow substantially in this area.

Neutra Corp. is also business partners with ZeroBlast, which uses a non-toxic antimicrobial solution to remove bacteria from surfaces. Another partner is Surface to Air Solutions – which is involved in green technology.

Neutra Corp. has been making good progress with businesses and potential future acquisitions, according to the company’s CEO Sydney Jim, and thus the company has canceled its reverse stock split and is instead going to focus on recent acquisitions.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• SinglePoint specializes in the acquisition of small to mid-sized companies, with a focus on new technologies
• The company attended the NACS (National Association of Convenience Stores) show to unveil its hemp cigarettes
• SinglePoint’s Direct Solar subsidiary continues to flourish

Based in Phoenix, Arizona, SinglePoint Inc. (OTCQB: SING) focuses on diversification into horizontal markets. The Company concentrates on researching opportunities where it can be active within an enterprise by influencing its direction and strategy. Specifically, as of late SinglePoint has shifted its focus to two promising products: its line of Pure American Hemp Cigarettes and its booming solar subsidiary, Direct Solar.

Recently, SinglePoint CEO Greg Lambrecht appeared on a segment of MoneyTV discussing the company’s attendance at a major trade show in Atlanta, Georgia – the National Association of Convenience Stores (NACS) show (http://ibn.fm/ECjQS). The NACS show took place October 1-4, 2019, and it attracted an estimated 23,500 industry stakeholders from around the world (http://ibn.fm/TKW01).

Lambrecht noted on the show that big retailers and distributors are going to the NACS show looking for a hemp cigarette manufacturer or distributor such as SinglePoint. The SING executive said that his company has put in considerable time preparing a direct-marketing effort to present its proprietary hemp product to attendees of the show.

SinglePoint is featuring its Pure American Hemp Cigarettes at the show, and according to Lambrecht, five distributors are seeking deals with the company before the NACS show even begins. This interest is a sign that SinglePoint is ahead of the game in this nascent market, with success coming before the show even hits full stride. The company has a meeting room set aside at NACS, and people have already signed up to meet with SinglePoint management to discuss the company’s products and initiatives.

What bodes well for SinglePoint is market supply and demand. The demand certainly appears to be there. A year ago, supply may have been an issue as the industry was getting on its feet. This year, however, Lambrecht noted that more farmers are growing hemp flower, and SinglePoint anticipates no problems meeting market demand.

Lambrecht also discussed SinglePoint’s subsidiary Direct Solar during the MoneyTV interview. Through Direct Solar, the company provides first-rate, cost-effective, solar power systems. At present, Direct Solar provides Arizona, parts of Texas and Southeast New York with commercial, municipal and residential services (http://ibn.fm/eI47K). For solar installation, Direct Solar handles paperwork, permits, system requirements, and everything else required.

Lambrecht noted that Direct Solar “continues to hit its numbers,” surpassing its forecasts every month as the subsidiary continues to sign new deals. Direct Solar also has launched a new commercial division, and the business section has 12 projects in its pipeline. Direct Solar remains a steady revenue profit center for SinglePoint, earning an estimated $1 million a month in contracts.

SinglePoint remains dedicated to its mission of providing return from diverse verticals. For investors, SinglePoint’s diversified model offers a premier platform for sustainable growth and expansion in important markets.

For more information, visit the company’s website at www.SinglePoint.com

NOTE TO INVESTORS: The latest news and updates relating to SING are available in the company’s newsroom at http://ibn.fm/SING

• Starr Insurance Companies, an insurance and investment powerhouse organized under the laws of Switzerland with offices on five continents, has contracted with CloudCommerce for data, messaging and digital marketing services
• Texas-based CloudCommerce offers end-to-end marketing solutions to help clients understand their customers’ interests and how to attract new customers with similar interests
• The company’s artificial intelligence enhanced marketing solutions and research tools are organized under CloudCommerce’s science and behavior platform, SWARM
• SWARM is a suite of solutions built on the metaphor of bee industriousness, serving as an example of the flagship suite’s ability to go out and gather information and bring it back to base to be digested and made available to end users

Business data technology company CloudCommerce Inc. (OTCQB: CLWD) is welcoming a new client to its family of data, messaging and digital marketing services under an agreement that will be effective over the next 12 months.

Insurance and investment powerhouse Starr Insurance Companies is asking CloudCommerce to help drive incremental sales growth by leveraging CloudCommerce’s digital marketing channels, drawing on the core capabilities of its wholly owned subsidiaries.

Cloud Commerce has been extending its potential to build business success stories through the development of advanced data science, behavioral science, artificial intelligence and market research techniques (http://ibn.fm/IgE1Y). Cloud Commerce’s outreach provides custom audiences for a strong variety of business activities.

The company is preparing to offer Tier II preferred stock through a filing with OTC Markets, asking $25 per share at the commencement, according to a September news release (http://ibn.fm/OFGh1).

Cloud Commerce launched its flagship service, an end-to-end data science and market behavior solution called SWARM, in July. SWARM draws on its AI and research tools to help businesses understand their customers’ interests and to develop new customers by locating consumers with similar interests. It provides solutions on marketing decisions and messages and helps businesses foster existing consumer trends for ongoing revenues strength (http://ibn.fm/XDLEo).

SWARM’s collective of marketing solutions is fashioned after the metaphor of beehive industriousness. Its tools go out to gather information from practically everywhere and brings it home to be digested and put to nourishing use. BUZZ is SWARM’s AI solution to deep dive market research analyzing customer data, social media activity and micro and macro trends. HIVE is its solution for targeting appropriate audiences, attracted by cultural “tribe” commonalities instead of geography-based catch-alls. And HONEY turns the core data into something that the user can utilize and digest in turn.

SWARM’s usage fees provide the company’s ongoing revenue, flexibly adapted to a client’s hourly or monthly needs. The company also obtains revenue from fees for designing, building and executing on digital marketing campaigns.

Starr Insurance Companies is a marketing name for Starr International Company, Inc.’s insurance and travel assistance companies and its subsidiaries, as well as for the investment business of C. V. Starr & Co., Inc. and its subsidiaries. Starr provides property, casualty and accident and health insurance products as well as a range of specialty coverages including aviation, marine, energy and excess casualty insurance (http://ibn.fm/uV2wU).

For more information, visit the company’s website at www.CloudCommerce.com

NOTE TO INVESTORS: The latest news and updates relating to CLWD are available in the company’s newsroom at http://ibn.fm/CLWD

• As the U.S. attempts to address its opioid crisis, the need for safe and effective pain management solutions is growing
• Endonovo Therapeutics is making significant progress toward commercializing its SofPulse® device that delivers pulsed electromagnetic frequencies for pain management
• Endonovo has completed clinical trials and is currently expanding commercialization of the device
• Several strategic appointments have also been made recently to strengthen the Endonovo team and the company’s clinical work

Endonovo Therapeutics Inc. (OTCQB: ENDV) is putting a lot of effort into the commercialization of SofPulse®, the company’s Electroceutical® wearable therapeutic device for pain management. The non-invasive, safe solution delivers pulsed electromagnetic frequencies for the effective management of pain and edema after surgery.

In August, Endonovo announced its Q2 financial results, showing growth in both revenue and gross profits. However, since the economic potential for a safe non-addictive alternative to opioids is significant, the company’s continued progress as it reaches developmental and test milestones is clearly the key focus. Over the second quarter of 2019, the company expanded SofPulse® commercialization and announced the first commercial sales of the device for post-operative pain and edema. “The opioid epidemic is a major issue in society today, making SofPulse® a significant alternative to postoperative pain management. We believe we have laid the foundation for rapid growth and expansion,” Endonovo CEO Alan Collier said in a company news release (http://ibn.fm/F4JX0).

The U.S. is currently undergoing a sweeping change in chronic pain management. Nearly 70,000 people die each year in the country from drug overdoses and prescription opioid medications are often blamed for accelerating this national catastrophe, the Washington Post reports (http://ibn.fm/xzyfP).

Changes in medical guidance pertaining to the administration of opioids are now contributing to millions of patients being tapered off opioid medications. There have even been suggestions from the psychiatric community to recognize opioid dependence as a distinct condition (http://ibn.fm/PoA3J). For many patients, the therapeutic use of opioid medications lasts years, even decades. These patients develop tolerance to the drugs and end up needing much larger doses than the ones set in the 2016 CDC guidelines.

Endonovo’s goal is to provide a safe and effective, hospital-tested pain management alternative. The company’s SofPulse® is clinically proven to reduce the need for potentially addictive pain medication and help speed up the post-surgery recovery process. Endonovo’s Electroceutical Therapy® has already been cleared by the U.S. Food and Drug Administration and is CE-marked in the European Economic Area for the palliative treatment of post-surgical pain and edema.

In September 2019, the company partnered up with the Veterans Healthcare Supply Solutions (VHSS) to initiate SofPulse® sales to Veterans Health Administration and military hospitals (http://ibn.fm/u0UIg). VHSS has over 30 years of healthcare distribution management experience. It represents leading manufacturers to federal government agencies and has an already well-established portfolio of diversified products.

At the same time, Endonovo has announced two new appointments to its scientific advisory board: Dr. Samir S. Awad and Dr. Geoffrey Abrams.

Awad served as the operative line executive, chief of general surgery and medical director of the Surgical Intensive Care Unit at Michael E. DeBakey VAMC. His specialty areas include surgical oncology, abdominal wall reconstruction, acute care surgery, laparoscopic and robotic surgical procedures. “Electroceutical® therapeutic devices are a fascinating frontier of pain management, and Endonovo’s SofPulse® approaches the industry in a safe manner while fighting the opioid epidemic head on,” Awad said in a news release regarding his appointment.

Abrams is an assistant professor of orthopedic surgery at the Stanford University School of Medicine and the director of sports medicine for the Stanford varsity athletes (http://ibn.fm/QqyN8). He is actively involved in research that examines the role of inflammatory mediators on cartilage and tendon damage.

For more information, visit the company’s website at www.Endonovo.com

NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at  http://ibn.fm/ENDV